ClinicalTrials.gg

Program

carfilzomib

Also written as “Carfilzomib”, “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)” and “Drug: Carfilzomib + Dexamethasone”.

Its studies are mostly in Multiple Myeloma · Amyloidosis · Small Cell Lung Carcinoma · Ovarian Neoplasms · Waldenstrom Macroglobulinemia, led by 5 companies.

Furthest: phase 4, since Apr 16, 201933 company-led studies, 4 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen230 open or runningphase 4since Apr 16, 2019Sep 6, 2005none ahead
AbbVie32 open or runningphase 3since Nov 28, 2023Sep 27, 2013Jun 2027phase 2 · NCT02899052
Criterium30 open or runningphase 2since Oct 19, 2011Oct 19, 2011none ahead
Oncotherapeutics20 open or runningphase 2since Jan 3, 2013Jan 3, 2013none ahead
Sanofi22 open or runningphase 2since Jan 20, 2023Jan 20, 2023Apr 1, 2027phase 2 · NCT06356571

Also a collaborator on its studies: Bristol-Myers Squibb and onyx-therapeutics-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Sep 6, 2005.

  1. Nov 6, 2013Phase 2 study in Small Cell Lung CarcinomaAmgen · NCT01987232 · 32 enrolled · United States, Canada, Russian Federation
  2. Dec 23, 2014Phase 1 study in Multiple MyelomaAmgen · NCT02335983 · 107 enrolled · United States
  3. Apr 6, 2015Phase 3 study in Multiple MyelomaAmgen · NCT02412878 · 478 enrolled · United States, Australia, Belgium and more
  4. Sep 1, 2016Phase 2 study in Multiple MyelomaAbbVie · NCT02899052 · 120 enrolled · United States, Australia, Hungary and more
  5. Nov 11, 2016Phase 3 study in RecurrenceAmgen · NCT03029234 · 126 enrolled · China
  6. Feb 27, 2017Phase 2 study in Multiple MyelomaOncotherapeutics · NCT03104270 · 13 enrolled · United States
  7. Apr 2, 2018Phase 2 study in RecurrenceAmgen · NCT03512353 · 7 enrolled · United States
  8. Jan 14, 2019Phase 3 study in RecurrenceAmgen · NCT03859427 · 454 enrolled · United States, Austria, Bulgaria and more
  9. Apr 16, 2019Phase 4 study in Multiple MyelomaAmgen · NCT03934684 · 101 enrolled · India
  10. Nov 22, 2019Phase 2 study in RecurrenceAmgen · NCT04191616 · 54 enrolled · United States, Denmark, Estonia and more
  11. Jan 20, 2023Sanofi's first study: phase 2 study in Multiple MyelomaNew to SanofiSanofi · NCT05704049 · 118 enrolled · Australia, Brazil, China and more
  12. Nov 28, 2023Phase 3 study in Multiple MyelomaAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
  13. Apr 5, 2024Phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571 · 64 enrolled · United States
  14. Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571

Ahead

  1. Apr 1, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571
  2. Jun 2027Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT02899052
  3. Dec 2027Primary completion: phase 3 study in Multiple MyelomaAbbVie · NCT06158841

TargetBeta

“26S proteasome inhibitor”ChEMBL 37, by rule

Other programs on the same 38 targets

ProgramCompanyFurthest phaseStudies
BortezomibruleJohnson & Johnsonphase 485

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06356571Plasma Cell Myeloma Refractory · United States2Active, not recruitingSanofiApr 1, 202764
NCT06158841Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingAbbVieDec 2027421
NCT05704049Multiple Myeloma · Australia, Brazil, China and more2Active, not recruitingSanofiDec 22, 2025118
NCT04191616Recurrence · United States, Denmark, Estonia and more2CompletedAmgenNov 30, 202254
NCT03934684Multiple Myeloma · India4CompletedAmgenMar 23, 2023101
NCT03859427Recurrence · United States, Austria, Bulgaria and more3CompletedAmgenMar 31, 2023454
NCT03512353Recurrence · United States2TerminatedAmgenJan 16, 20207
NCT03104270Multiple Myeloma · United States2TerminatedOncotherapeuticsOct 25, 201913
NCT03029234Recurrence · China3CompletedAmgenNov 5, 2018126
NCT02899052Multiple Myeloma · United States, Australia, Hungary and more2Active, not recruitingAbbVieJun 2027120
NCT02412878Multiple Myeloma · United States, Australia, Belgium and more3CompletedAmgenJun 15, 2017478
NCT02335983Multiple Myeloma · United States1CompletedAmgenOct 28, 2019107
NCT01987232Small Cell Lung Carcinoma · United States, Canada, Russian Federation2CompletedAmgenAug 201632
NCT01980589Multiple Myeloma · United States1CompletedAmgenMar 201622
NCT01962792Multiple Myeloma · United States, Canada2CompletedAbbVieMar 201984
NCT01949545Hematologic Neoplasms · United States, France, Netherlands and more1CompletedAmgenAug 201546
NCT01949532Multiple Myeloma · United States, Australia, Canada1CompletedAmgenApr 201526
NCT01818752Multiple Myeloma · United States, Argentina, Australia and more3CompletedAmgenJul 15, 2016955
NCT01789242Amyloidosis · United States1CompletedCriteriumDec 201632
NCT01792102Multiple Myeloma · United States2UNKNOWNOncotherapeuticsDec 201838
NCT01677858Multiple Myeloma · United States2CompletedAmgenJul 22, 2016116
NCT01660750Multiple Myeloma · United States1CompletedCriteriumAug 201529
NCT01568866Multiple Myeloma · United States, Australia, Austria and more3CompletedAmgenNov 10, 2014929
NCT01464034Multiple Myeloma · United States2TerminatedCriteriumJul 2020136
NCT01302392Multiple Myeloma · Australia, Austria, Belgium and more3CompletedAmgenJul 2014315
NCT01080391Multiple Myeloma · United States, Austria, Belgium and more3CompletedAmgenJun 16, 2014792
NCT00884312Multiple Myeloma · United States, Canada2CompletedAmgenMay 17, 2017101
NCT00721734Multiple Myeloma · United States2CompletedAmgenNov 201250
NCT00603447Multiple Myeloma · United States, Canada1CompletedAmgenMay 201384
NCT00531284Ovarian Neoplasms · United States2CompletedAmgenOct 2014184
NCT00530816Multiple Myeloma · United States, Canada2CompletedAmgenJan 2013164
NCT00511238Multiple Myeloma · United States, Canada2CompletedAmgenNov 2010312
NCT00150462Waldenstrom Macroglobulinemia · United States1CompletedAmgenOct 200948

How it is read

Names in the registry

  • “Carfilzomib”, 34 entries
  • “carfilzomib”, 3 entries
  • “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)”, 1 entry
  • “Drug: Carfilzomib + Dexamethasone”, 1 entry
  • “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.